Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…
NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm,…
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiologys Annual Scientific Session 2025
− New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the…
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
– BRTX-100 is the first and only stem cell product candidate cleared…
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
--- The United States FDA Approves the Initiation for Phase II Efficacy…
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a…
FDA Approves Samsung Bioepis OSPOMYV, XBRYK (denosumab-dssb), a Biosimilar to Prolia and Xgeva
OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA)…